Evidence map›Paper›PMID 36377880›Full record

ArticlemSphere2022

A New Benzothiazolthiazolidine Derivative, 11726172, Is Active

Elena G Salina, Umberto Postiglione, Laurent R Chiarelli, Deborah Recchia, Monika Záhorszká, Alexander Lepioshkin, Natalia Monakhova, Adrian Pál, Alessio Porta, Giuseppe Zanoni and 6 more

Abstract read
In one paragraph

Article in mSphere, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. ACS infectious diseases · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Elena G Salina *Department of Biology and Biotechnology Lazzaro Spallanzani, University of Paviagrid.8982.b, Pavia, Italy.
Umberto Postiglione *Department of Biology and Biotechnology Lazzaro Spallanzani, University of Paviagrid.8982.b, Pavia, Italy.
Laurent R ChiarelliDepartment of Biology and Biotechnology Lazzaro Spallanzani, University of Paviagrid.8982.b, Pavia, Italy.ORCID 0000-0003-0348-9764
Deborah RecchiaDepartment of Biology and Biotechnology Lazzaro Spallanzani, University of Paviagrid.8982.b, Pavia, Italy.
Monika ZáhorszkáDepartment of Biochemistry, Faculty of Natural Sciences, Comenius Universitygrid.7634.6 Bratislava, Bratislava, Slovakia.
Alexander LepioshkinBach Institute of Biochemistry, Research Centre of Biotechnology RAS, Moscow, Russia.
Natalia MonakhovaBach Institute of Biochemistry, Research Centre of Biotechnology RAS, Moscow, Russia.
Adrian PálDepartment of Biochemistry, Faculty of Natural Sciences, Comenius Universitygrid.7634.6 Bratislava, Bratislava, Slovakia.
Alessio PortaDepartment of Chemistry, University of Paviagrid.8982.b, Pavia, Italy.
Giuseppe ZanoniDepartment of Chemistry, University of Paviagrid.8982.b, Pavia, Italy.
Jana KordulákováDepartment of Biochemistry, Faculty of Natural Sciences, Comenius Universitygrid.7634.6 Bratislava, Bratislava, Slovakia.
Elena KazakovaBach Institute of Biochemistry, Research Centre of Biotechnology RAS, Moscow, Russia.
Davide SasseraDepartment of Biology and Biotechnology Lazzaro Spallanzani, University of Paviagrid.8982.b, Pavia, Italy.
Maria Rosalia PascaDepartment of Biology and Biotechnology Lazzaro Spallanzani, University of Paviagrid.8982.b, Pavia, Italy.ORCID 0000-0002-8906-4937
Vadim MakarovBach Institute of Biochemistry, Research Centre of Biotechnology RAS, Moscow, Russia.ORCID 0000-0001-8746-2694
Giulia DegiacomiDepartment of Biology and Biotechnology Lazzaro Spallanzani, University of Paviagrid.8982.b, Pavia, Italy.ORCID 0000-0002-3626-8311

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tuberculosis (TB) still poses a global menace as one of the deadliest infectious diseases. A quarter of the human population is indeed latently infected with Mycobacterium tuberculosis. People with latent infection have a 5 to 10% lifetime risk of becoming ill with TB, representing a reservoir for TB active infection. This is a worrisome problem to overcome in the case of relapse; unfortunately, few drugs are effective against nonreplicating M. tuberculosis cells. Novel strategies to combat TB, including its latent form, are urgently needed. In response to the lack of new effective drugs and after screening about 500 original chemical molecules, we selected a compound, 11726172, that is endowed with potent antitubercular activity against M. tuberculosis both

Indexed as

COVID-19Latent TuberculosisMycobacterium tuberculosisTuberculosisAntitubercular AgentsHumansAntitubercular Agentsantitubercular drugcopperlatencyMycobacterium tuberculosisnonreplicating cells

Identifiers

PMID36377880
PMCPMC9769805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.